

Product information

Leaflet

GlyCare™ 2FL

The most abundant
fucosylated HMO
in human milk

Early life nutrition innovation from dsm-
firmenich

Providing the best infant nutrition is vital for all families. That's why dsm-firmenich is proud to offer GlyCare™ HMOs. These compounds are developed with science-backed quality and safety at their core. As a fully integrated manufacturer with one of the broadest HMO offerings, dsm-firmenich can reliably provide ease-of-scale no matter the size of your business. Partner with us to get your products one step closer to what nature intended.

Partner with dsm-firmenich for access to our broad portfolio of products, customized solutions, and expert services aimed at supporting your entire product life cycle, from concept to consumption.

www.dsm-firmenich.com/health-nutrition-care



dsm-firmenich 

Human Milk Oligosaccharides (HMOs): delivering the benefits nature intended

Uniquely human

- HMOs are complex carbohydrates found in human breastmilk
- No other mammal has near the concentration and complexity of structures in their milk¹⁻⁶

Abundance and diversity in human milk

- 3rd largest component of human milk⁷
- >200 different HMOs identified in human milk, a diversity not seen in other animal milks⁴⁻⁶
- Variation in concentration and diversity occurs over lactation period, by maternal genetics, geographic region, and ethnicity^{8,9}

Complex structures with potential functional benefits

- Help establish a balanced early-life microbiota^{10,11}
- Contribute to immune system support¹²⁻¹⁶

Of all HMOs, 2'-Fucosyllactose (2'FL) is the most abundant in human milk*†

- Found in the milk of most of lactating women^{8,9}
- May play a role in digestive and immune health^{13,17,18}

* Around 2g/L. † Presence of 2FL is dependent upon maternal genotype and, thus, may be population specific.

Potential functional benefits of GlyCare™ 2FL, as demonstrated in pre-clinical and clinical trials



- A combination of GlyCare™ 2FL and GlyCare™ LNnT may reduce incidence of colic in infants born via cesarean section¹⁹
- Emerging science suggests a potential role in normal gut motility²⁰



- Emerging evidence suggests a potential role in cognitive development²¹⁻²³
- Helps balance gut microbiota by stimulating beneficial bacteria such as bifidobacteria²⁴



- Emerging scientific evidence suggests a potential positive role in inflammation^{25,26}
- In a clinical study supplementing infant formula with GlyCare™ 2'FL and GlyCare™ LNnT, there were significantly fewer parental reports of bronchitis, lower respiratory tract infections, and antipyretic and antibiotic use¹⁹

- May help support a normal immune system^{27,28}

- May support gut barrier function^{29,30}


- May help support normal immune function^{17,31}



Breastmilk – the gold standard

The best nutrition for infants is a mother's breastmilk, which includes essential nutrients important for an infant's growth and development. Recent research shows that one of the largest differentiating features of breastmilk compared to cow's milk-based infant formula is the concentration and variety of milk oligosaccharides.³² Until recently, HMOs have not been part of infant formula.

You can see the macronutrients composition in human milk in the chart to the right:



GlyCare™ DFL product information

- 5 years of shelf life from production date
- Purity levels range from 96–98% depending on the variant
- Available in different variants such as KfP, hypoallergenic, crystallized and amorphous powder
- White, homogenous powder with a neutral to slightly sweet taste
- Manufactured without contact to latex, bisphenol A, or phthalates
- This product is free from: Animal derived ingredients (ADI), Allergens (except milk),[§] Genetically modified organisms (GMO)*
- Contains up to 3% lactose[§]

[§] according to EC regulation 1169/2011 annex II
[¥] according to EC regulation 1829/2003 and 1830/2003




Broad product portfolio and a leading HMO innovator



Proven, reliable supply that scales with you



Highest safety and quality standards



Largest global market access: 160+ countries*

* We are continuously expanding our global approval footprint across application areas. For more details, please ask for our Regulatory Overview.

For more information, get in touch with your dsm-firmenich representative, or visit our website www.dsm.com/human-nutrition

dsm-firmenich GlyCare™ HMOs are produced to the highest quality of certifications, approvals, and procedures



ISO
9001:2015



FSSC
22000



SMETA



Halal



Kosher

The full GlyCare™ HMO portfolio

- GlyCare™ 2FL
- GlyCare™ LNT
- GlyCare™ 2FL/DFL
- GlyCare™ 6SL
- GlyCare™ 3SL
- GlyCare™ LNT
- GlyCare™ 3FL
- GlyCare™ LNFP I

References

1. T. Urashima, T. Saito, T. Nakamura, and M. Messer, "Oligosaccharides of milk and colostrum in non-human mammals," *Glycoconjugate Journal*, vol. 18, no. 5, Springer, pp. 357–371, 2001, doi:10.1023/A:1014881913541.
2. D. S. Newburg et al., "Milk oligosaccharides across species," *Pediatr. Res.*, vol. 45, no. 5, pp. 745–745, May 1999, doi:10.1203/00006450-199905010-00044.
3. S. Albrecht et al., "A comparative study of free oligosaccharides in the milk of domestic animals," *Br. J. Nutr.*, vol. 111, no. 7, pp. 1313–1328, Apr. 2014, doi:10.1017/S0007114513003772.
4. N. Tao et al., "Evolutionary glycomics: Characterization of milk oligosaccharides in primates," *J. Proteome Res.*, vol. 10, no. 4, pp. 1548–1557, 2011, doi:10.1021/pr1009367.
5. T. Urashima, S. Asakuma, F. Leo, K. Fukuda, M. Messer, and O. T. Oftedal, "The Predominance of Type I Oligosaccharides Is a Feature Specific to Human Breast Milk," *Am. Soc. Nutr. Adv. Nutr.*, vol. 3, pp. 473S–482S, 2012, doi:10.3945/an.111.001412.
6. P. Gagnew et al., "Human-specific Regulation of a2–6-linked Sialic Acids," *J. Biol. Chem.*, vol. 278, no. 48, pp. 48245–48250, 2003, doi:10.1074/jbc.M309813200.
7. Hegar, B., Wibowo, Y., Basrowi, R. W., Ranuh, R. G., Sudarmo, S. M., Munasir, Z., Atthiyah, A. F., Widodo, A. D., Supriatno, Kadim, M., Suryawan, A., Diana, N. R., Manoppo, C., & Vandenplas, Y. (2019). The Role of Two Human Milk Oligosaccharides, 2'-Fucosyllactose and Lacto-N-Neotetraose, in Infant Nutrition. *Pediatric gastroenterology, hepatology & nutrition*, 22(4), 330–340. <https://doi.org/10.5223/pghn.2019.22.4.330>
8. Vandenplas, Y., Berger, B., Carnielli, V. P., Ksiazyk, J., Lagström, H., Sanchez Luna, M., Migacheva, N., Mosselmans, J., Picaud, J., Possner, M., Singhal, A., & Wabitsch, M. (2018). Human Milk Oligosaccharides: 2'-Fucosyllactose (2'-FL) and Lacto-N-Neotetraose (LNNT) in Infant Formula. *Nutrients*, 10(9)10.3390/nu10091161
9. Soyylmaz, Buket, et al. "The Mean of Milk: A Review of Human Milk Oligosaccharide Concentrations throughout Lactation." *Nutrients*, 2021, doi:10.3390/nu13082737
10. Berger, Bernard, et al. "Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk to Require Antibiotics." *MBio*, vol. 11, no. 2, 2020, pp. 1–18, doi:10.1128/mBio.03196-19.
11. Bezirtzoglou, Eugenia, et al. "Anaerobe Microbiota pro Fi Le in Faces of Breast- and Formula-Fed Newborns by Using FI Uorescence In Situ Hybridization (FISH)." *Anaerobe*, vol. 17, no. 6, Elsevier Ltd, 2011, pp. 478–82, doi:10.1016/j.anaerobe.2011.03.009.
12. Zhang, Bin, et al. "Human Milk Oligosaccharides and Infant Gut Microbiota: Molecular Structures, Utilization Strategies and Immune Function." *Carbohydrate Polymers*, vol. 276, no. October 2021, Elsevier Ltd, 2022, p. 118738, doi:10.1016/j.carbpol.2021.118738.
13. Zuurveld, Marit, et al. "Immunomodulation by Human Milk Oligosaccharides: The Potential Role in Prevention of Allergic Diseases." *Frontiers in Immunology*, vol. 11, no. May, 2020, doi:10.3389/fimmu.2020.00801.
14. Derya, S. M., Spiegel, H., Hanisch, F. G., Morozov, V., Schrotten, H., Jennewein, S., & Parschat, K. (2020). Biotechnologically produced fucosylated oligosaccharides inhibit the binding of human noroviruses to their natural receptors. *Journal of Biotechnology*, 318(November 2019), 31–38. <https://doi.org/10.1016/j.jbiotec.2020.05.001>
15. Koromylova, A., Tripathi, S., Morozov, V., Schrotten, H., & Hansman, G. S. (2017). Human norovirus inhibition by a human milk oligosaccharide. *Virology*, 508(April), 81–89. <https://doi.org/10.1016/j.virol.2017.04.032>
16. Yang, B., Chung, H., & Yang, K. D. (2009). Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. *Virology Journal*, 6, 1–6. <https://doi.org/10.1186/1743-422X-6-141>
17. Mezoff, Ethan A., et al. "The Human Milk Oligosaccharide 2'-Fucosyllactose Augments the Adaptive Response to Extensive Intestinal." *American Journal of Physiology - Gastrointestinal and Liver Physiology*, vol. 310, no. 6, 2016, pp. G427–38, doi:10.1152/ajpgi.00305.2015.
18. Marriage, Barbara J., et al. "Infants Fed a Lower Calorie Formula with 2'FL Show Growth and 2'FL Uptake Like Breast-Fed Infants." *Journal of Pediatric Gastroenterology and Nutrition*, vol. 61, no. 6, 2015, pp. 649–58, doi:10.1097/MPG.0000000000000889.
19. Puccio, Giuseppe, et al. "Effects of Infant Formula with Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial." *Journal of Pediatric Gastroenterology and Nutrition*, vol. 64, no. 4, Lippincott Williams and Wilkins, Apr. 2017, pp. 624–31, doi:10.1097/MPG.0000000000001520.
20. Bienenstock, John, et al. "Fucosylated but Not Sialylated Milk Oligosaccharides Diminish Colon Motor Contractions." *PLoS ONE*, vol. 8, no. 10, 2013, pp. 1–9, doi:10.1371/journal.pone.0076236.
21. Berger, Paige K., et al. "Human Milk Oligosaccharide 2'-Fucosyllactose Links Feedings at 1 Month to Cognitive Development at 24 Months in Infants of Normal and Overweight Mothers." *PLoS ONE*, vol. 15, no. 2, 2020, pp. 1–12, doi:10.1371/journal.pone.0228323.
22. Oliveros, Elena, et al. "Oral Supplementation of 2'-Fucosyllactose during Lactation Improves Memory and Learning in Rats." *Journal of Nutritional Biochemistry*, vol. 31, Elsevier Inc., 2016, pp. 20–27, doi:10.1016/j.jnutbio.2015.12.014.
23. Vázquez, Enrique, et al. "Effects of a Human Milk Oligosaccharide, 2'-Fucosyllactose, on Hippocampal Long-Term Potentiation and Learning Capabilities in Rodents." *Journal of Nutritional Biochemistry*, vol. 26, no. 5, Elsevier Inc., 2015, pp. 455–65, doi:10.1016/j.jnutbio.2014.11.016.
24. Yu, Zhuo Teng, et al. "The Principal Fucosylated Oligosaccharides of Human Milk Exhibit Prebiotic Properties on Cultured Infant Microbiota." *Glycobiology*, vol. 23, no. 2, 2013, pp. 169–77, doi:10.1093/glycob/cws138.
25. Sodhi, Chhinder P., et al. "The Human Milk Oligosaccharides 2'-Fucosyllactose and 6'-Sialyllactose Protect against the Development of Necrotizing Enterocolitis by Inhibiting Toll-like Receptor 4 Signaling." *Pediatric Research*, no. August 2019, 2020, pp. 1–11, doi:10.1038/s41390-020-0852-3.
26. Grabinger, Thomas, et al. "Alleviation of Intestinal Inflammation by Oral Supplementation with 2-Fucosyllactose in Mice." *Frontiers in Microbiology*, vol. 10, no. JUN, 2019, pp. 1–14, doi:10.3389/fmicb.2019.01385.
27. Castillo-Courtade, L., et al. "Attenuation of Food Allergy Symptoms Following Treatment with Human Milk Oligosaccharides in a Mouse Model." *Allergy: European Journal of Allergy and Clinical Immunology*, vol. 70, no. 9, 2015, pp. 1091–102, doi:10.1111/all.12650.
28. Sprenger, Norbert, et al. "FUT2-Dependent Breast Milk Oligosaccharides and Allergy at 2 and 5 Years of Age in Infants with High Hereditary Allergy Risk." *Eur J Nutr*, vol. 56, 2017, pp. 1293–301, doi:10.1007/s00394-016-1180-6.
29. Kong, Chunli, et al. "Modulation of Intestinal Epithelial Glycocalyx Development by Human Milk Oligosaccharides and Non-Digestible Carbohydrates." *Molecular Nutrition and Food Research*, vol. 63, no. 17, 2019, pp. 1–24, doi:10.1002/mnfr.201900303.
30. Holscher, Hannah D., et al. "Human Milk Oligosaccharides Influence Maturation of Human Intestinal Caco-2Bbe and HT-29 Cell Lines." *Journal of Nutrition*, vol. 144, no. 5, 2014, pp. 586–91, doi:10.3945/jn.113.189704.
31. Goehring, Karen C., et al. "Similar to Those Who Are Breastfed, Infants Fed a Formula Containing 2'-Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized Controlled Trial." *Journal of Nutrition*, vol. 146, no. 12, 2016, pp. 2559–66, doi:10.3945/jn.116.236919.
32. Bode, L. "Human Milk Oligosaccharides and Their Beneficial Effects." *Handbook of Dietary and Nutritional Aspects of Human Breast Milk*, no.

Disclaimer

Although dsm-firmenich-firmenich has used diligent care to ensure that the information provided herein is accurate and up to date, dsm-firmenich makes no representation or warranty of the accuracy, reliability, or completeness of the information. This brochure only contains scientific and technical information for business to business use. Country or region-specific information should also be considered when labeling or advertising to final consumers. This publication does not constitute or provide scientific or medical advice, diagnosis, or treatment and is distributed without warranty of any kind, either expressly or implied. In no event shall dsm-firmenich be liable for any damages arising from the reader's reliance upon, or use of, these materials. The reader shall be solely responsible for any interpretation or use of the material contained herein. The content of this document is subject to change without further notice. Please contact your local dsm-firmenich representative for more details. All trademarks listed in this brochure are either registered trademarks, trademarks or licensed trademarks of dsm-firmenich group of companies in the Netherlands and/or other countries, unless explicitly stated otherwise.

© dsm-firmenich Nutritional Products 2022